What are the recommended management steps for a 75‑year‑old woman with osteopenia of the left hip?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Osteopenia in a 75-Year-Old Woman

For a 75-year-old woman with osteopenia of the left hip, you should calculate her FRAX score immediately and initiate pharmacologic treatment with a bisphosphonate (alendronate, risedronate, or zoledronic acid) if her 10-year risk of major osteoporotic fracture is ≥20% or hip fracture risk is ≥3% 1, 2, 3.

Risk Assessment Algorithm

At age 75, this patient requires immediate fracture risk stratification:

  1. Calculate FRAX score using her age, BMD T-score, and clinical risk factors (parental hip fracture history, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes) 1, 2

  2. Treatment thresholds for osteopenia (T-score between -1.0 and -2.5):

    • 10-year hip fracture risk ≥3%, OR
    • 10-year major osteoporotic fracture risk ≥20% 1, 2, 3

  3. Additional high-risk features warranting treatment regardless of FRAX:

    • History of any fragility fracture (even with osteopenia)
    • Very low body weight (<127 lbs)
    • Currently on medications causing bone loss 1

Universal Baseline Interventions (Start Immediately)

Regardless of whether pharmacologic treatment is initiated:

  • Calcium: 1,200 mg daily (dietary plus supplement if needed)
  • Vitamin D: 800 IU daily (target serum level ≥20 ng/mL) 1
  • Weight-bearing and resistance exercise regularly 2
  • Smoking cessation if applicable 2
  • Limit alcohol to ≤2 units per day 2
  • Falls risk assessment and prevention strategies - critical at age 75 1, 2

Pharmacologic Treatment Decision

If FRAX Meets Treatment Thresholds:

First-line options (choose based on patient preference and contraindications):

  • Alendronate 70 mg weekly (oral) 1, 4, 2
  • Risedronate 35 mg weekly (oral) 1, 4, 2
  • Zoledronic acid 5 mg every 2 years IV (for osteopenia dosing) 1, 2

The 2017 ACP guideline specifically addresses osteopenic women ≥65 years, recommending an individualized approach with bisphosphonates when FRAX thresholds are met 4. The 2020 AACE guideline more definitively recommends treatment at these thresholds 2.

Key prescribing considerations:

  • Oral bisphosphonates require: taking on empty stomach, remaining upright 30 minutes, adequate renal function (CrCl >35 mL/min for zoledronic acid)
  • Contraindications: esophageal abnormalities, inability to stand/sit upright 30 minutes, hypocalcemia 1
  • Check serum calcium and vitamin D before starting; correct deficiencies first 1

If FRAX Does NOT Meet Treatment Thresholds:

  • Continue universal interventions above
  • Repeat DEXA in 1-2 years to monitor for progression 1, 2
  • Reassess FRAX annually as age alone increases fracture risk

Monitoring During Treatment

  • Do NOT repeat DEXA during first 5 years of treatment - not supported by evidence 4
  • Treat for 5 years initially, then reassess fracture risk to determine if drug holiday is appropriate 4, 2
  • Consider checking bone turnover markers (serum CTX) at 3-6 months to assess adherence if compliance is uncertain 5

Critical Pitfalls to Avoid

  1. Don't dismiss osteopenia as "not needing treatment" - at age 75, many fractures occur in the osteopenic range, particularly if FRAX is elevated 6

  2. Don't forget to check for secondary causes: thyroid function, vitamin D level, calcium, complete blood count, comprehensive metabolic panel to rule out conditions like hyperparathyroidism, multiple myeloma, or malabsorption 2

  3. Don't overlook vertebral fractures - obtain lateral spine X-ray if she has height loss >4 cm, kyphosis, or back pain, as prevalent vertebral fractures dramatically increase treatment indication 2

  4. Age 75 is high-risk by definition - even with osteopenia, her age alone substantially increases fracture probability. The 2023 ACP guideline emphasizes that treatment decisions in osteopenic women ≥65 should weigh baseline fracture risk heavily 3

  5. Falls prevention is paramount - at 75, most fractures result from falls. Assess gait, balance, vision, medications causing dizziness, and home safety 1, 2

Evidence Strength

The recommendation to use FRAX thresholds (≥20% major osteoporotic fracture or ≥3% hip fracture) for treating osteopenic postmenopausal women comes from multiple high-quality guidelines 1, 2. The 2020 AACE guideline provides the most definitive treatment algorithm for this scenario 2. While the 2023 ACP guideline takes a more conditional stance on treating osteopenia 3, it acknowledges that bisphosphonates reduce fracture risk, and at age 75, the benefit-risk ratio strongly favors treatment when FRAX thresholds are met.

The evidence for bisphosphonates preventing hip and vertebral fractures in women with osteoporosis is high-quality 4, and this benefit extends to high-risk osteopenic women, though the absolute risk reduction is smaller 3, 6.

References

1
Guideline

acog releases practice bulletin on osteoporosis.

American family physician, 2013

2
Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Related Questions

In a patient with lumbar spine bone mineral density within normal limits and a right femoral neck bone mineral density of 0.759 g/cm² (T‑score −1.8) indicating osteopenia, what treatment should be initiated?
What is the recommended management for a 61-year-old postmenopausal female with a 10-year major osteoporotic fracture risk of 9.2% and a hip fracture risk of 1%?
With a 10‑year major osteoporotic fracture risk of 20.3% and a hip fracture risk of 4.9%, what pharmacologic treatment and preventive measures should be recommended?
What is the recommended osteoporosis treatment for a 71-year-old woman with lumbar spine T-score 0.1, bilateral hip T-scores –2.2, 10-year hip fracture risk 7%, major osteoporotic fracture risk 20%, vitamin D 38 ng/mL, calcium 9.3 mg/dL, phosphate 3.7 mg/dL, parathyroid hormone 38 pg/mL, and elevated bone turnover markers?
In a 67-year-old patient with a body mass index of 31.8 kg/m2 and no bone mineral density measurement, who has a 10-year major osteoporotic fracture risk of 3.1% and a hip fracture risk of 0.7%, what management should be undertaken?
In an asymptomatic patient with cicatricial atelectasis who has 100% oxygen saturation on room air, is a pulmonary function test required for cardiopulmonary clearance before a fractional curettage procedure?
For hospitalized patients needing short‑term relaxation and sleep, should I use Atarax (hydroxyzine hydrochloride) or Vistaril (hydroxyzine pamoate)?
In a 16-year-old female with a 2 cm left hepatic lobe mass suspected to be a hemangioma, should an abdominal ultrasound be performed before discharge from the emergency department?
In an adult patient with atrial fibrillation, hypertension, and heart failure with preserved ejection fraction (EF 55‑60 %), who is already taking torsemide, spironolactone, and lisinopril but still has uncontrolled blood pressure (150/80 mm Hg) and bilateral lower‑leg edema, what non‑diuretic heart medication can be added to improve his condition?
In a healthy 16‑year‑old female with a 2 cm left‑lobe hepatic hemangioma, could it cause elevated liver enzymes?
Can Infuvite (multivitamin additive) in D5W be administered concurrently with Clinimix E (amino‑acid parenteral nutrition)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.